Drotaverine HCL-DROTAFIX Tablet

Each tablet contains:

  • Drotaverine HCL 80mg
  • Mefenamic Acid 250 mg


DROTAFIX Tablet is a combination of Drotaverine HCL and Mefanamic Acid.

Drotaverine is classified as selective phosphodiesterase inhibitor and acts as antispasmodic prescribed for pain and dysfunction caused by smooth muscle spasm.

Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID) that alleviates pain symptoms by inhibition of pain mediators associated with both isoforms of COX and prevents formation of prostaglandins and is used to treat mild to moderate pain, including menstrual pain, and is sometimes used to prevent migraines associated with menstruation.


DROTAFIX is indicated mainly for the treatment of biliary tract spasm, gastrointestinal spasm, urinary tract spasm, and pain due to primary dysmenorrhea.


The adult oral dose of DROTAFIX is one tablet taken every 6-8 hours for more than 2-3 days. The dose for children more than 14 years is same as adult dose. The formula is best taken with a full glass of water or with food.


DROTAFIX should not be administered in the following cases:

  • DROTAFIX is not recommended in asthma patients.
  • DROTAFIX should not be prescribed to individuals whom have history of GI (Gastrointestinal) bleeding.
  • DROTAFIX is contraindicated in patients with renal impairment.
  • DROTAFIX should not be used in individuals with hypersensitivity.


Caution should be exercised when DROTAFIX is prescribed at the same time with Magnesium hydroxide cause increase in drug absorption.

Caution should be exercised when prescribing DROTAFIX to patients with lithium toxicity as it increases lithium toxicity which can be fatal.

DROTAFIX contains drotaverine for which dosage adjustments may be required in patients with renal impairment since drotaverine and its metabolites are excreted by kidneys.

Drotaverin has the potential to decrease the antiparkinsonian effect of levodopa resulting in increase in rigidity and tremor. In patients of parkinson DROTAFIX is not recommended.


The most frequently reported adverse reactions associated with the use of mefenamic acid (in DROTOFIX) are diarrhea, nausea with or without vomiting, and abdominal pain. Other GI reactions less frequently reported include anorexia, pyrosis, flatulence and constipation. GI ulceration with and without hemorrhage can also occur with mefenamic acid (in DROTAFIX). Oral drotaverine (in DROVERA MF) has very less adverse event incidence reported.


DROTAFIX should not to be used in pregnancy. The use of mefenamic acid in late pregnancy is not recommended because of the effects on the fetal cardiovascular system of drugs of this class. There are no controlled data in human pregnancy. Mefenamic acid is only recommended for use during pregnancy when benefit outweighs risk.


DROTAFIX tablets are available in a 10X12ís blister packing


The medical information on this site is provided as an information resource only, and is not to be used or relied on for any diagnostic or treatment purposes. This information is not intended to be patient education, does not create any patient-physician relationship, and should not be used as a substitute for professional diagnosis and treatment. Please note it is dangerous to take any medication without doctorís prescription or professional advice from a registered health practitioner. Always follow the instructions of physician / doctor / registered medical practitioner before using any medicine. Do not exceed the recommended dosage. Keep all medicines away from your children. Store as recommended. Please consult your health care provider, before making any healthcare decisions or for guidance about a specific medical condition. The allopathic medicine as per the law in India must be sold by retail pharmacies holding valid trading drug license only.